Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19 : a three-arm randomized clinical trial
© 2021. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences..
BACKGROUND AND OBJECTIVES: Corticosteroids are commonly used in the treatment of hospitalized patients with COVID-19. The goals of the present study were to compare the efficacy and safety of different doses of dexamethasone in the treatment of patients with a diagnosis of moderate to severe COVID-19.
METHODS: Hospitalized patients with a diagnosis of moderate to severe COVID-19 were assigned to intravenous low-dose (8 mg once daily), intermediate-dose (8 mg twice daily) or high-dose (8 mg thrice daily) dexamethasone for up to 10 days or until hospital discharge. Clinical response, 60-day survival and adverse effects were the main outcomes of the study.
RESULTS: In the competing risk survival analysis, patients in the low-dose group had a higher clinical response than the high-dose group when considering death as a competing risk (HR = 2.03, 95% CI: 1.23-3.33, p = 0.03). Also, the survival was significantly longer in the low-dose group than the high-dose group (HR = 0.36, 95% CI = 0.15-0.83, p = 0.02). Leukocytosis and hyperglycemia were the most common side effects of dexamethasone. Although the incidence was not significantly different between the groups, some adverse effects were numerically higher in the intermediate-dose and high-dose groups than in the low-dose group.
CONCLUSIONS: Higher doses of dexamethasone not only failed to improve efficacy but also resulted in an increase in the number of adverse events and worsen survival in hospitalized patients with moderate to severe COVID-19 compared to the low-dose dexamethasone. (IRCT20100228003449N31).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Pharmacological reports : PR - 74(2022), 1 vom: 27. Feb., Seite 229-240 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Toroghi, Negar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 27.01.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s43440-021-00341-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333747623 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333747623 | ||
| 003 | DE-627 | ||
| 005 | 20231225222302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s43440-021-00341-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333747623 | ||
| 035 | |a (NLM)34837648 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Toroghi, Negar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19 |b a three-arm randomized clinical trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.01.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: Corticosteroids are commonly used in the treatment of hospitalized patients with COVID-19. The goals of the present study were to compare the efficacy and safety of different doses of dexamethasone in the treatment of patients with a diagnosis of moderate to severe COVID-19 | ||
| 520 | |a METHODS: Hospitalized patients with a diagnosis of moderate to severe COVID-19 were assigned to intravenous low-dose (8 mg once daily), intermediate-dose (8 mg twice daily) or high-dose (8 mg thrice daily) dexamethasone for up to 10 days or until hospital discharge. Clinical response, 60-day survival and adverse effects were the main outcomes of the study | ||
| 520 | |a RESULTS: In the competing risk survival analysis, patients in the low-dose group had a higher clinical response than the high-dose group when considering death as a competing risk (HR = 2.03, 95% CI: 1.23-3.33, p = 0.03). Also, the survival was significantly longer in the low-dose group than the high-dose group (HR = 0.36, 95% CI = 0.15-0.83, p = 0.02). Leukocytosis and hyperglycemia were the most common side effects of dexamethasone. Although the incidence was not significantly different between the groups, some adverse effects were numerically higher in the intermediate-dose and high-dose groups than in the low-dose group | ||
| 520 | |a CONCLUSIONS: Higher doses of dexamethasone not only failed to improve efficacy but also resulted in an increase in the number of adverse events and worsen survival in hospitalized patients with moderate to severe COVID-19 compared to the low-dose dexamethasone. (IRCT20100228003449N31) | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a High-dose | |
| 650 | 4 | |a Intermediate-dose | |
| 650 | 4 | |a Low-dose | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Abbasian, Ladan |e verfasserin |4 aut | |
| 700 | 1 | |a Nourian, Anahid |e verfasserin |4 aut | |
| 700 | 1 | |a Davoudi-Monfared, Effat |e verfasserin |4 aut | |
| 700 | 1 | |a Khalili, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Hasannezhad, Malihe |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiasvand, Fereshteh |e verfasserin |4 aut | |
| 700 | 1 | |a Jafari, Sirous |e verfasserin |4 aut | |
| 700 | 1 | |a Emadi-Kouchak, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Yekaninejad, Mir Saeed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological reports : PR |d 2005 |g 74(2022), 1 vom: 27. Feb., Seite 229-240 |w (DE-627)NLM154978965 |x 2299-5684 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2022 |g number:1 |g day:27 |g month:02 |g pages:229-240 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s43440-021-00341-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2022 |e 1 |b 27 |c 02 |h 229-240 | ||